PURPOSE: To explore cancer stem cell susceptibility to a host's cytotoxic T lymphocyte (CTL)-mediated immune response. METHODS: We compared the susceptibility of putative CSC generated from cancer cell lines to immunologic recognition and killing by alloantigen-specific CD8(+) CTL. CSC-enriched spheroid culture-derived cells (SDC) exhibited higher expression of ALDH, ICAM1 and of stem/progenitor cell markers on all 3 tumor cell lines investigated and lower MHC class I on the cervical cancer cell line as compared to their monolayer-derived cells (MDC). RESULTS: The expression of ICAM1 and MHCI was upregulated by IFN-γ treatment. CSC populations were less sensitive to MHC class I-restricted alloantigen-specific CD8(+) CTL lysis as compared to matched MDC. IFN-γ pretreatment resulted in over-proportionally enhanced lysis of SDC. Finally, the subset of ALDH(high) expressing SDC presented more sensitivity toward CD8(+) CTL killing than the ALDH(low) SDC. CONCLUSIONS: Tumor therapy resistance has been attributed to cancer stem cells (CSC). We show in vitro susceptibility of CSC to CTL-mediated lysis. Immunotherapy targeting of ALDH(+) CSC may therefore be a promising approach. Our results and method may be helpful for the development and optimization of adjuvants, as here exemplified for INF-γ, for CSC-targeted vaccines, independent of the availability of CSC-specific antigens.
PURPOSE: To explore cancer stem cell susceptibility to a host's cytotoxic T lymphocyte (CTL)-mediated immune response. METHODS: We compared the susceptibility of putative CSC generated from cancer cell lines to immunologic recognition and killing by alloantigen-specific CD8(+) CTL. CSC-enriched spheroid culture-derived cells (SDC) exhibited higher expression of ALDH, ICAM1 and of stem/progenitor cell markers on all 3 tumor cell lines investigated and lower MHC class I on the cervical cancer cell line as compared to their monolayer-derived cells (MDC). RESULTS: The expression of ICAM1 and MHCI was upregulated by IFN-γ treatment. CSC populations were less sensitive to MHC class I-restricted alloantigen-specific CD8(+) CTL lysis as compared to matched MDC. IFN-γ pretreatment resulted in over-proportionally enhanced lysis of SDC. Finally, the subset of ALDH(high) expressing SDC presented more sensitivity toward CD8(+) CTL killing than the ALDH(low) SDC. CONCLUSIONS:Tumor therapy resistance has been attributed to cancer stem cells (CSC). We show in vitro susceptibility of CSC to CTL-mediated lysis. Immunotherapy targeting of ALDH(+) CSC may therefore be a promising approach. Our results and method may be helpful for the development and optimization of adjuvants, as here exemplified for INF-γ, for CSC-targeted vaccines, independent of the availability of CSC-specific antigens.
Authors: Laurie A Boyer; Tong Ihn Lee; Megan F Cole; Sarah E Johnstone; Stuart S Levine; Jacob P Zucker; Matthew G Guenther; Roshan M Kumar; Heather L Murray; Richard G Jenner; David K Gifford; Douglas A Melton; Rudolf Jaenisch; Richard A Young Journal: Cell Date: 2005-09-23 Impact factor: 41.582
Authors: Carmen Visus; Yangyang Wang; Antonio Lozano-Leon; Robert L Ferris; Susan Silver; Miroslaw J Szczepanski; Randall E Brand; Cristina R Ferrone; Theresa L Whiteside; Soldano Ferrone; Albert B DeLeo; Xinhui Wang Journal: Clin Cancer Res Date: 2011-08-19 Impact factor: 12.531
Authors: Carmen Visus; Diasuke Ito; Andrew Amoscato; Malgorzata Maciejewska-Franczak; Ahmed Abdelsalem; Rajiv Dhir; Dong M Shin; Vera S Donnenberg; Theresa L Whiteside; Albert B DeLeo Journal: Cancer Res Date: 2007-11-01 Impact factor: 12.701
Authors: Emina H Huang; Mark J Hynes; Tao Zhang; Christophe Ginestier; Gabriela Dontu; Henry Appelman; Jeremy Z Fields; Max S Wicha; Bruce M Boman Journal: Cancer Res Date: 2009-03-31 Impact factor: 12.701
Authors: Chao Chen; Yan Wei; Michael Hummel; Thomas K Hoffmann; Manfred Gross; Andreas M Kaufmann; Andreas E Albers Journal: PLoS One Date: 2011-01-27 Impact factor: 3.240
Authors: Yangyang Hu; Lin Lu; Yang Xia; Xin Chen; Alfred E Chang; Robert E Hollingsworth; Elaine Hurt; John Owen; Jeffrey S Moyer; Mark E P Prince; Fu Dai; Yangyi Bao; Yi Wang; Joel Whitfield; Jian-Chuan Xia; Shiang Huang; Max S Wicha; Qiao Li Journal: Cancer Res Date: 2016-06-20 Impact factor: 12.701
Authors: Erik Ames; Robert J Canter; Steven K Grossenbacher; Stephanie Mac; Rachel C Smith; Arta M Monjazeb; Mingyi Chen; William J Murphy Journal: Oncoimmunology Date: 2015-06-05 Impact factor: 8.110
Authors: Emilie T E Gross; Carlos D Peinado; Yujin Jung; Semi Han; Beichen Liu; Endi K Santosa; Jack D Bui Journal: Oncoimmunology Date: 2018-10-31 Impact factor: 8.110
Authors: Erik Ames; Robert J Canter; Steven K Grossenbacher; Stephanie Mac; Mingyi Chen; Rachel C Smith; Takeshi Hagino; Jessica Perez-Cunningham; Gail D Sckisel; Shiro Urayama; Arta M Monjazeb; Ruben C Fragoso; Thomas J Sayers; William J Murphy Journal: J Immunol Date: 2015-09-11 Impact factor: 5.422
Authors: Mark E P Prince; Li Zhou; Jeffrey S Moyer; Huimin Tao; Lin Lu; John Owen; Martin Etigen; Fang Zheng; Alfred E Chang; Jianchuan Xia; Gregory Wolf; Max S Wicha; Shiang Huang; Xiubao Ren; Qiao Li Journal: Oral Oncol Date: 2016-08 Impact factor: 5.337